Pharmalucence, which has sterile injectable capacity in the US, has been acquired by one of the subsidiaries of Sun Pharma, the Mumbai-based firm said in a statement.
The company, however, did not disclose the financial details of the deal.
Earlier this year, Sun Pharma had acquired Ranbaxy Laboratories in an all-stock transaction with a total equity value of $3.2 billion along with debt of $800 million, taking the overall deal value to $4 billion.
Sun Pharma shares were trading at Rs 748.30, up 1.30 per cent from its previous close.